We are here to help you. We invite you to learn more about our Board of Directors, full- and part-time staff members.
Brian GM Durie, MD
Chairman of the Board
Professor of Medicine
Dr. Durie is the Medical Director for AMyC and Specialist in Multiple Myeloma and Related Disorders for Cedars-Sinai Outpatient Cancer Center in Los Angeles, California. He is Co-Chair of the Myeloma Committee for SWOG, and Chairman of the International Myeloma Foundation.
Susie Novis Durie
President & Chief Executive Officer
Founder and President
International Myeloma Foundation
Susie Novis Durie founded the IMF in 1990 with her late husband, Brian Novis, and Brian G.M. Durie. M.D., as a means to advance myeloma research and to develop and implement patient and physician educational programs in myeloma.
In 1992, Novis Durie was elected Executive Director of the IMF and today holds the title of President. Under her direction, the IMF has continued to experience impressive growth, and the programs that she has developed have become models for other organizations worldwide. The program she is proudest of is the Patient & Family Seminars. Attending a physician conference in London, she saw doctors “meeting the professors” and thought patients should also have the opportunity to meet the professors, learn about myeloma, and share experiences with other patients. In 1994 she held the first ever Patient & Family Seminar which was held in Los Angeles, and shortly thereafter began holding seminars across the US. In 1997 she expanded seminar program to the UK. Today patient seminars are held around the world.
Susie Novis Durie has testified before the United States Congress on behalf of greater resources for myeloma research. In 2002, she was presented with the Joseph Michaeli Award for her outstanding contributions to the understanding, advancement and treatment of myeloma. Investor’s Business Daily featured Susie Novis Durie in its Leaders & Success column, and she has been recognized in many articles worldwide for the important work that she has done on behalf of myeloma patients and their families.
President, International Myeloma Foundation Latin America and President, Instituto Espaço de Vida
Yelak Biru believes through research advocacy Myeloma patients will be able to better balance quality of life with treatment outcome while helping accelerate both translational and basic Myeloma research. Yelak understands the need and is passionate about improving access to life saving cancer drugs globally and advancing the innovation pipeline through research and patient participation. He is a member of the IMF Global Myeloma Action Network (GMAN), a patient advisor for pharmaceutical companies, a liaison for the Smart Patients myeloma community, and the leader of the North Texas Myeloma Support Group.
Prof. Mario Boccadoro
Professor of Medicine
Prof. Boccadoro is Head of the Hematology Section of the Oncology Division at the University of Torino. He is the founder of the Italian Myeloma Study Group, the first research consortium in Italy and one of the first in Europe. He is the recipient of the Sixth Annual Robert A. Kyle Lifetime Achievement Award.
Loraine Alterman Boyle
Mrs. Boyle became involved with the IMF when her husband, the actor Peter Boyle, was diagnosed with myeloma. Although Peter lost his battle, she has continued her commitment to the IMF and chairs "A Tribute to Peter Boyle," the annual comedy show to benefit the foundation. A former rock journalist for Rolling Stone and the New York Times, Mrs. Boyle is a producer of Tony winning Broadway musical "Memphis" and writes blogs for the Huffington Post. A Barnard College graduate, she is also active in community organizations.
Aldo Del Col
Foundation Co-Founder and Chief Scientific Advisor
Aldo Del Col co-founded Myeloma Canada in 2004. He previously served as Myeloma Canada’s Executive Director and currently serves as Chief Scientific Advisor, drawing upon his scientific and pharmaceutical background to drive research focused on optimizing patient outcomes. Mr. Del Col, who was diagnosed with myeloma in 2002, also serves as the patient representative for hematology on the National Cancer Institute of Canada (NCIC) Clinical Trials Group and is a member of the Global Myeloma Alliance Steering Committee. He received a Bachelor of Science in Pharmacy from the University of Toronto and a Master in Business Administration from the York University Schulich School of Business.
Marketing and Product Management
Mr. DiCicilia has worked in product marketing and product management in the telecommunications, document management and software industries for over thirty years. He has successfully brought to market a number of products and services while working for a variety of large and medium sized companies.
Jason S. Katz
Jason Katz is VP of App and Digital Marketing at Houghton Mifflin Harcourt, a leader in education and kids media. As a creative executive, he brings with him 15+ years of marketing and technology experience in both Fortune 100 and startups. As a member of the IMF Board of Directors, Jason carries on the tradition of his father, Michael S. Katz, longtime IMF Director, highly accomplished and widely respected myeloma patient advocate, and beloved member of the IMF family.
Benson Klein, JD
Mr. Klein is a Principal Member of the law firm Ward & Klein, Chartered. He received his J.D. from Georgetown University College of Law in 1970 and is a member of the Maryland State Bar Association, the District of Columbia Bar Association, and the Montgomery County Bar Association. He has served and continues to serve on the board of organizations such as Eagle Bank, Chairman of the Eagle Bank Healthcare Advisory Board, President of the Shady Grove Adventist Hospital Foundation, Shady Grove Adventist Hospital Governance Board, and other organizations in both the business and non-profit sectors.
Andy Kuzneski, III
Investment and Banking
Mr. Kuzneski is currently active in the insurance, investment and banking industries. He is a Principal at Kuzneski Financial Group, an insurance broker, and President of Greyhawk Capital, a provider of equity capital and advice to seed and early stage growth companies. He is also President and board member of Berkshire Securities, a private investment company that has invested in Pennsylvania-based community and regional banks for over 30 years.
Robert A. Kyle, MD
Professor of Medicine – Hematologist/Oncologist
Dr. Kyle is Professor of Medicine and Laboratory Medicine at the Mayo Medical School, Rochester, Minnesota. He received his M.D. with Distinction from Northwestern University Medical School. Dr. Kyle has published over 800 articles relating to hematology and oncology, along with an additional 1100 abstracts and editorials. He has served both as a Guest Lecturer and as a Visiting Professor throughout the world. Dr. Kyle currently serves as a director and member of the Scientific Advisory Board for the International Myeloma Foundation. He has been Chairman of the Myeloma Committee of the Eastern Cooperative Oncology Group, a member of the Editorial Board of Leukemia, and Secretary General of International Society of Hematology, Inter-American Division.
Prof. Heinz Ludwig
Professor of Medicine
Dr. Ludwig is Director of the Department of Medicine I, Center of Oncology and Hematology at Wilheminenspital, Vienna. He is past-president of the European Society for Medical Oncology (ESMO) and the recipient of the Fifth Annual Robert A. Kyle Lifetime Achievement Award.
Edith Mitchell, MD
Professor of Medicine
Dr. Mitchell is a clinical professor at Jefferson Medical College in Philadelphia, Pennsylvania. She is Board Certified in both Internal Medicine and Medical Oncology. After receiving her M.D. from the Medical College of Virginia, Dr. Mitchell served first active duty, then reserve duty, as a physician with the United States Air Force for a total of nine years. She was honored with several prestigious military decorations during her time of service, and was subsequently honored with the Distinguished Service Award from the Air National Guard.
Charles Newman, MS
Mr. Newman has been an entrepreneur since starting his first company while a college undergraduate in 1961. He has been instrumental in the development of the secondary user market for used wireless handsets and is the founder, Chief Executive Officer, and President of ReCellular Inc., the largest company in this market, currently processing over 300,000 phones per month. In addition, Mr. Newman is a principal of the Newman Computer Group and was a founder and member of the Board of Directors of the Bank of Ann Arbor. Mr. Newman received his B.S. in 1963, and his M.S. in 1964, both from the University of Michigan.
S. Vincent Rajkumar, MD
Professor of Medicine
Dr Rajkumar is Professor of Medicine at the Mayo Clinic, Rochester, Minnesota, and Chair of the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He is also Chair of the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. He has published more than 230 peer-reviewed papers primarily in the field of myeloma and related plasma cell disorders. Dr Rajkumar is the Section Editor for multiple myeloma and related disorders for Leukemia and is an Associate Editor for the Mayo Clinic Proceedings.
Mr. Robinson currently serves as Senior Vice President, International Television Distribution at Twentieth Century Fox in Los Angeles, California.
Prior to his current position at 20th Century Fox, he held senior executive posts at Warner Bros. and The Walt Disney Company. Before working in the television business, Mr. Robinson had a successful career in investment banking, working in the mergers and acquisitions group of UK firm Kleinwort Benson and Smith Barney Harris Upham. He holds a B.A. cum laude in Economics from Harvard University and an MBA from London Business School.
E. Michael D. Scott
Scientific & Medical Communications
Mr. Scott is a senior health-care communication strategist with Calcium, a Philadelphia-based health-care communications group. He is also a board member of the National Organization for Rare Disorders (NORD), a member of the American Society of Hematology (ASH), and an associate member of the American Society for Clinical Oncology (ASCO). He graduated from the University of Sussex, where he earned an honors degree in biochemistry.